Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

@article{Arkenau2008EfficacyOO,
  title={Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.},
  author={Hendrik-Tobias Arkenau and Dirk V. Arnold and Jim Cassidy and Eduardo Diaz-Rubio and Jean-yves Douillard and Howard S. Hochster and Andrea A Martoni and Arnhild Grothey and Axel Hinke and Wolff -H. Schmiegel and H Schmoll and Rainer Porschen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 36},
  pages={
          5910-7
        }
}
PURPOSE Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer. This meta-analysis compared the efficacy of CAP/OX compared with infusional FU/OX. PATIENTS AND METHODS This analysis compared all published CAP/OX versus infusional FU/OX regimens. A total of 3,494 patients (FU, n = 1,737; CAP, n = 1,757) were analyzed for response rate (RR), progression-free (PFS… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 70 CITATIONS, ESTIMATED 58% COVERAGE

Advances in the management of colorectal cancer: from biology to treatment

  • International Journal of Colorectal Disease
  • 2014
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

  • Clinical and Translational Oncology
  • 2015
VIEW 15 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer

  • Cancer Chemotherapy and Pharmacology
  • 2016
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.

  • European journal of cancer care
  • 2015
VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Potential regional differences for the tolerability profiles of fluoropyrimidines.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 2 EXCERPTS

Randomized comparison of capecitabine versus fluorouracil/leucovorin in combination with oxaliplatin in metastatic colorectal cancer patients: Southern Italy Cooperative Oncology Group trial 0401

P Comella, B Massidda, G Filipelli
  • Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January
  • 2008
VIEW 1 EXCERPT

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 1 EXCERPT

domized phase III study of capecitabine plus oxaliplatin compared with fluorouracil / folinic acid plus oxaliplatin as first - line therapy for metastatic colorectal cancer

Clarke S Cassidy, E Diaz-Rubio
  • J Clin Oncol
  • 2008

Similar Papers

Loading similar papers…